GENE ONLINE|News &
Opinion
Blog

Feature
AstraZeneca Welcomes Neurofibromatosis And Asthma Treatment Approvals in Japan
2022-09-28
Arsenal Biosciences Announced Another $70 million Collaboration, This Time With Genentech
2022-09-27
Biogen Concludes $900 Million Settlement Before Posting Positive Data From Alzheimer’s Trial
2022-09-28
Seagen Strikes Potential $650 million Deal with LAVA Therapeutics for Cancer Treatment
On September 26, Seagen announced an exclusive agreement with LAVA Therapeutics for the development, manufacturing, and commercialization of LAVA-1223, a targeted therapy for multiple kinds …

Home Read More »

2022-09-26
Acticor Enrolls First Patient in Phase 2/3 Stroke Treatment Study
2022-09-27
Special
Biogen Concludes $900 Million Settlement Before Posting Positive Data From Alzheimer’s Trial
In a flurry of highs and lows for Biogen this week, the company voluntarily paid a $900 million settlement in a lawsuit brought about by a former employee regarding alleged paid kickbacks for physicians willing to prescribe the company’s multiple sclerosis drugs. At the other end of Biogen’s week, the company reported positive Phase 3 confirmatory trial results from its newest Alzheimer’s drug developed with Eisai, lecanemab, which is set for a regulatory decision in January next year. 
2022-09-28
ESMO 2022: Promising Trials Highlights That Are Worth Following
This year's event, organized by the European Society for Medical Oncology (ESMO), took place in Paris from September 9 to 13. This congress is an oncology event for international HCPs, the majority from Europe. 

As the opening conference remarked, sustainability will be the heart of many discussions. “Sustainability is about maintaining important, high-quality processes over time. In oncology, seeing the rise in cancer cases, we need to ask ourselves how we can ensure the essential process of caring for patients can be maintained,” said ESMO President Prof. Solange Peters.

For cancers that are not currently avoidable, screening and early detection can both maximize individuals’ chances of survival and alleviate the burden on health systems by reducing the proportion of patients with advanced diseases who require costly, chronic therapies and care.  

This year has been a fructiferous year for oncologists, with many positive clinical trial results and upgrades from previous clinical trials. As many new drugs are ongoing, we’ll focus on those discussed most lately. 

2022-09-21
The COVID-19 Pandemic: Is Omicron the Last Variant?
The COVID-19 pandemic saw the rise of multiple strains that put the companies manufacturing vaccines through their paces to keep up. With the FDA approving new vaccines for the latest substrains of the Omicron Variant, it seems that COVID-19 Cases are finally slowing down. These Emergency Use Authorizations were pushed through in a manner of days, marking them as some of the fastest ever in FDA history. However, they were based upon mountains of prior research done on their predecessors for prior strains as well as the heavily mutated Omicron Strains.
How do these vaccines function differently from their prior counterparts? And will these boosters bring about the end of the COVID-19 pandemic after so many strain mutations?
2022-09-16
LATEST
AstraZeneca Welcomes Neurofibromatosis And Asthma Treatment Approvals in Japan
2022-09-28
Biogen Concludes $900 Million Settlement Before Posting Positive Data From Alzheimer’s Trial
2022-09-28
Arsenal Biosciences Announced Another $70 million Collaboration, This Time With Genentech
2022-09-27
Sciwind Biosciences And SynerK Join Forces To Develop siRNA Therapeutics
2022-09-27
Acticor Enrolls First Patient in Phase 2/3 Stroke Treatment Study
2022-09-27
Daiichi Sankyo Wins Approval For Cancer Treatment in Japan
2022-09-26
Seagen Strikes Potential $650 million Deal with LAVA Therapeutics for Cancer Treatment
2022-09-26
Deals
Arsenal Biosciences Announced Another $70 million Collaboration, This Time With Genentech
2022-09-27
Theravance Allots $250 Million to Repurchase Shares, Removing GSK as a Shareholder
2022-09-20
Big Pharma-Backed Capstan Launches With $165 Million To Combine Cell Therapy And mRNA Technology
2022-09-15
Shenzhen Joincare Plots $300 Million IPO On Swiss Exchange
2022-06-20
Forbion Looks to Fund IPO Ambitious Companies With Its €470 Million Fund
2022-06-10
Belite Bio Clears Biopharma IPO Drought, with HilleVax and Tenon Medical Close Behind
2022-05-03
Roche Buys Good Therapeutics For $250 Million Upfront, Obtains Immune Stimulating Antibody Conjugate Program
2022-09-08
European Commission Prohibits Illumina’s Acquisition of GRAIL After The Company’s Win Against The FTC
2022-09-07
CVS Beats Amazon in Signify Bidding War with $8 Billion Acquisition Offer
2022-09-06
Ranking & Reports
2026: The Promise of Synthetic Biology
2022-08-11
Market Insight on FDA-approvals: Rise of First-in-class and Regenerative Innovations
2022-03-17
Cure or Poison? New Ventures Go IPO Continuously As “Psychedelics” Enter the Mental Health Market
2022-03-09
Categories
Defeating Head and Neck Cancer, From Combination Therapy to Photoimmunotherapy
2022-09-15Partner
Scaling up Korea’s Biotech Presence in The Global Value Chain, an Interview with Seung Kyou Lee, Vice President of KoreaBIO
2022-08-31
How the Greater Tokyo Region Could Be the Next Promising Biocommunity
2022-07-19
AstraZeneca Welcomes Neurofibromatosis And Asthma Treatment Approvals in Japan
2022-09-28
Sciwind Biosciences And SynerK Join Forces To Develop siRNA Therapeutics
2022-09-27
China’s Biocytogen And FineImmune Bring TCR-Mimic Antibodies And Cell Therapy Together
2022-09-16
AstraZeneca Welcomes Neurofibromatosis And Asthma Treatment Approvals in Japan
2022-09-28
Biogen Concludes $900 Million Settlement Before Posting Positive Data From Alzheimer’s Trial
2022-09-28
Acticor Enrolls First Patient in Phase 2/3 Stroke Treatment Study
2022-09-27
Sanofi Invests in Innovent to Gain Stronger Foothold in China
2022-08-05
Everest, Calliditas Win First Approval for Rare Kidney Disease Drug in Europe
2022-07-18
Zhiyi Biotech Finishes Series B Funding With $45 Million For Live Biotherapeutics
2022-07-11
Boston’s Manifold Bio Secures $40M to Tackle Translational Obstacles
2022-07-15
US Bio-Entrepreneur Program Launches in the UK
2022-06-30
Ultima Genomics Promises $100 Genome After Raising $600 Million
2022-06-01
Government Agencies Spring into Action After Biomanufacturing Executive Order
2022-09-14
WuXi Biologics Adds Microbial Fermentation to CDMO Offering in Hangzhou
2022-07-05
Spying Rapid Growth, Avantor Invests in Manufacturing Hub in Singapore
2022-05-05
Seagen Strikes Potential $650 million Deal with LAVA Therapeutics for Cancer Treatment
2022-09-26
AstraZeneca Blocks Ionis’ Hypercholesterolemia Treatment from Moving into a Phase 3 Study
2022-09-23
Gilead Forking Over $280 million to Everest to Regain Rights to Breast Cancer Treatment
2022-08-16
Bacteria-Derived Protocells Mark Breakthrough in Synthetic Biology
2022-09-23
Overcoming Immune Evasion in CAR-T Therapies with Groundbreaking New Discoveries
2022-09-22
Promising CHIP Protein Could Act as ‘Molecular Switch’ to Longevity
2022-09-21
Growing Number of Monkeypox Tests Available to Researchers
2022-08-22
Taiwan’s CancerFree Bio Showcases World’s First Commercialized Personalized Cancer Profile
2022-08-01
BD, CerTest Commercialize Research-Use Monkeypox Test Amidst Rising Cases
2022-07-29
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!